Joëlle Dhanis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Joëlle Dhanis has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Anke Smits
BHGOC, Barts Health NHS Trust, London E1 1FR, UK
1 shared publication - Cornelia G. Verhoef
Radboud University Medical Centre
1 shared publication - Heidi Rütten
Department of Radiation Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
1 shared publication - Johanna M. A. Pijnenborg
Department of Obstetrics and Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands
1 shared publication - Petronella Beatrix Ottevanger
Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands
1 shared publication - Willem Jan van Weelden
Department of Obstetrics and Gynaecology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.
1 shared publication
Latest Publications
- Open Access
Recurrent Endometrial Cancer: Local and Systemic Treatment Options
The treatment of recurrent endometrial cancer is a challenge. Because of earlier treatments and the site of locoregional recurrence, in the vaginal vault or pelvis, morbidity can be high. A total of about 4 to 20% of the patients with endometrial cancer develop a locoregional recurrence, mostly among patients with locally advanced disease. The treatment options are dependent on previous treatments and the site of recurrence. Local and locoregional recurrences can be treated curatively with surgery or (chemo)radiotherapy with acceptable toxicity and control rates. Distant recurrences can be treated with palliative systemic therapy, i.e., first-line chemotherapy or hormonal therapy. Based on the tumor characteristics and molecular profile, there can be a role for immunotherapy. The evidence on targeted therapy is limited, with no approved treatment in the current guidelines. In selected cases, there might be an indication for local treatment in oligometastatic disease. Because of the novel techniques in radiotherapy, disease control can often be achieved at limited toxicity. Further studies are warranted to analyze the survival outcome and toxicity of newer treatment strategies. Patient selection is very important in deciding which treatment is of most benefit, and better prediction models based on the patient- and tumor characteristics are necessary.
Open AccessRecurrent Endometrial Cancer: Local and Systemic Treatment Options
The treatment of recurrent endometrial cancer is a challenge. Because of earlier treatments and the site of locoregional recurrence, in the vaginal vault or pelvis, morbidity can be high. A total of about 4 to 20% of the patients with endometrial cancer develop a locoregional recurrence, mostly among patients with locally advanced disease. The treatment options are dependent on previous treatments and the site of recurrence. Local and locoregional recurrences can be treated curatively with surgery or (chemo)radiotherapy with acceptable toxicity and control rates. Distant recurrences can be treated with palliative systemic therapy, i.e., first-line chemotherapy or hormonal therapy. Based on the tumor characteristics and molecular profile, there can be a role for immunotherapy. The evidence on targeted therapy is limited, with no approved treatment in the current guidelines. In selected cases, there might be an indication for local treatment in oligometastatic disease. Because of the novel techniques in radiotherapy, disease control can often be achieved at limited toxicity. Further studies are warranted to analyze the survival outcome and toxicity of newer treatment strategies. Patient selection is very important in deciding which treatment is of most benefit, and better prediction models based on the patient- and tumor characteristics are necessary.